<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04454229</url>
  </required_header>
  <id_info>
    <org_study_id>PALACE1</org_study_id>
    <nct_id>NCT04454229</nct_id>
  </id_info>
  <brief_title>The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge</brief_title>
  <acronym>PALACE</acronym>
  <official_title>The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge - An International Multicenter Randomized Control Trial - The PALACE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whilst validated tools exist to enable inpatient penicillin assessment and de-labelling,
      limited evidence is available regarding the safety and efficacy in the outpatient clinic. The
      ability to deliver point-of-care penicillin allergy testing for a large cohort of patients,
      without skin testing, will improve patient access to testing and utilization of preferred
      penicillin antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient-reported penicillin allergies result in poor health outcomes for patients and drive
      inappropriate antibiotic prescribing, antimicrobial resistance and healthcare costs. Our
      group has internally and externally validated a novel penicillin allergy clinician decision
      rule (PEN-FAST) that is able to identify low risk penicillin allergies with a negative
      predictive value of 96% (95%; 94-98%). Therefore, whilst validated tools exist to enable
      inpatient penicillin assessment and de-labelling, limited evidence is available regarding the
      safety and efficacy in the outpatient clinic. The ability to deliver point-of-care penicillin
      allergy testing for a large cohort of patients, without skin testing, will improve patient
      access to testing and utilization of preferred penicillin antibiotics.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Direct oral challenge in patients with PEN-Fast less than 3
Eligible patients referred to the outpatient clinic reporting a penicillin allergy will be identified and assessed with a standard clinical history and the calculation of the PEN-FAST score. PEN-FAST is a three-point clinical assessment tool recently externally validated in a multicenter study, with a PEN-FAST score of &lt; 3 associated with 96.7% negative predictive value.
Intervention:
The patient will receive a single dose of oral penicillin, following baseline vital signs (i.e. temperature, heart rate, blood pressure, respiratory rate, skin check).
Nursing staff will repeat vital signs as needed and after oral challenge while observing for signs of an immune mediated adverse reaction.
If at any stage an antibiotic associated adverse event is noted, standard of care treatment is offered by the attending clinicians (ex. adrenalin for immediate hypersensitivity reaction).</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in the proportion of positive oral challenges (i.e. immune-mediated reaction)</measure>
    <time_frame>up to 48H after oral challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients referred to the outpatient allergy clinic that are eligible for intervention (i.e randomization) as per protocol [Eligibility to screened ratio]</measure>
    <time_frame>Before randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of recruitment defined as the proportion of patients consenting to participate in the study as per protocol from eligible patients. [Recruitment to eligibility ratio].</measure>
    <time_frame>Before randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of intervention delivery defined as the proportion of patients randomized to the intervention arm who had the intervention delivered as per protocol. [Intervention to recruitment ratio]</measure>
    <time_frame>Before randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with a penicillin allergy who experience an antibiotic associated immune mediated adverse event OR severe adverse drug reaction as per protocol definitions.</measure>
    <time_frame>Up to 48h after the drug challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients that will respect the protocol (protocol compliance)</measure>
    <time_frame>Up to 48h after the drug challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patient with positive Penicillin Skin Testing</measure>
    <time_frame>Up to 48h after the drug challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with non-immune mediated positive oral challenges</measure>
    <time_frame>Up to 48h after the drug challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with severe adverse reaction - anaphylaxis/death</measure>
    <time_frame>Up to 48h after the drug challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to delabelling</measure>
    <time_frame>Up to 48h after the drug challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of appointments required for Penicillin delabelling</measure>
    <time_frame>Up to 48h after the drug challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment with the Drug Hypersensitivity Quality of Life Questionnaire</measure>
    <time_frame>Up to 48h after the drug challenge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Hypersensitivity, Immediate</condition>
  <condition>Hypersensitivity, Delayed</condition>
  <condition>Hypersensitivity Response</condition>
  <arm_group>
    <arm_group_label>Direct oral antibiotic challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct oral antibiotic (penicillin) challenge in patients with PEN-Fast less than 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care: skin testing and, if negative, oral challenge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Direct oral penicillin challenge</intervention_name>
    <description>The patient will receive a single dose of oral penicillin, following baseline vital signs.</description>
    <arm_group_label>Direct oral antibiotic challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients referred to the outpatient allergy clinic for a penicillin allergy
             history;

          2. Willing and able to give consent.

        Exclusion Criteria:

          1. Patient age is &lt; 18 years;

          2. Patients with a PEN-FAST score ?3

          3. Pregnancy;

          4. Any other illness that, in the investigator's judgement, will substantially increase
             the risk associated with subject's participation in this study;

          5. Patients with history of type A adverse drug reaction, drug-associated anaphylaxis,
             idiopathic urticaria/anaphylaxis, mastocytosis, serum sickness, blistering skin
             eruption or acute interstitial nephritis;

          6. Patients with a concurrent history of immune-mediated cephalosporin allergy;

          7. Patients where the allergy history was not able to be confirmed with patient;

          8. Patients on concurrent antihistamine therapy;

          9. Patients receiving more than stress dose steroids (i.e. &gt; 50mg QID hydrocortisone [or
             steroid equivalent]).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Copaescu, MD</last_name>
    <phone>+610466067000</phone>
    <email>ana.copaescu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Trubiano, MD PhD</last_name>
    <phone>+61394966709</phone>
    <email>Jason.TRUBIANO@austin.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Phillips, MD</last_name>
      <email>elizabeth.j.phillips@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Cosby Stone, MD, MPH</last_name>
      <email>cosby.a.stone@vumc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana Copaescu, MD</last_name>
      <phone>0466067000</phone>
      <email>Ana.copaescu@austin.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Jason Trubiano, MD PhD</last_name>
      <phone>(03) 94966709</phone>
      <email>Jason.trubiano@austin.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jason Trubiano, MD PhD</last_name>
      <phone>(03) 94966709</phone>
      <email>Jason.trubiano@austin.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Ana Copaescu, MD</last_name>
      <phone>0466067000</phone>
      <email>Ana.copaescu@austin.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph De Luca, MD</last_name>
      <phone>(03) 93493199</phone>
      <email>Joseph.DeLuca@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Bégin, MD PhD</last_name>
      <email>philippe.begin@umontreal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Christos Tsoukas, MD</last_name>
      <email>christos.tsoukas@mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Trubiano JA, Vogrin S, Chua KYL, Bourke J, Yun J, Douglas A, Stone CA, Yu R, Groenendijk L, Holmes NE, Phillips EJ. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Intern Med. 2020 Mar 16. doi: 10.1001/jamainternmed.2020.0403. [Epub ahead of print]</citation>
    <PMID>32176248</PMID>
  </results_reference>
  <results_reference>
    <citation>Devchand M, Urbancic KF, Khumra S, Douglas AP, Smibert O, Cohen E, Sutherland M, Phillips EJ, Trubiano JA. Pathways to improved antibiotic allergy and antimicrobial stewardship practice: The validation of a beta-lactam antibiotic allergy assessment tool. J Allergy Clin Immunol Pract. 2019 Mar;7(3):1063-1065.e5. doi: 10.1016/j.jaip.2018.07.048. Epub 2018 Aug 29.</citation>
    <PMID>30172019</PMID>
  </results_reference>
  <results_reference>
    <citation>Trubiano JA, Smibert O, Douglas A, Devchand M, Lambros B, Holmes NE, Chua KY, Phillips EJ, Slavin MA. The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study. Open Forum Infect Dis. 2018 Nov 17;5(12):ofy306. doi: 10.1093/ofid/ofy306. eCollection 2018 Dec.</citation>
    <PMID>30547046</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>July 26, 2020</last_update_submitted>
  <last_update_submitted_qc>July 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Austin Health</investigator_affiliation>
    <investigator_full_name>Ana Copaescu</investigator_full_name>
    <investigator_title>Investigator, Allergy-Immunology Fellow</investigator_title>
  </responsible_party>
  <keyword>penicillin</keyword>
  <keyword>Low Risk allergy</keyword>
  <keyword>direct oral challenge</keyword>
  <keyword>standard of care</keyword>
  <keyword>outpatient clinic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Hypersensitivity, Immediate</mesh_term>
    <mesh_term>Hypersensitivity, Delayed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

